You cannot register for this webinar

Atara is focused on applying Epstein-Barr virus T-cell biology and novel chimeric antigen receptor (CAR) technologies to enter new frontiers of cell therapy for patients with cancer and autoimmune diseases. With cutting edge-science and differentiated approach, we are the first company in the world to receive regulatory approval for an allogeneic T-cell immunotherapy with the approval of Ebvallo™ by the European Commission. Atara also recently submitted the first allogeneic T-cell therapy (tab-cel) BLA to the U.S. FDA and, if approved, tab-cel would be the first approved therapy in the U.S. for EBV+ post-transplant lymphoproliferative disease. Our advanced and versatile T-cell platform, which has been used to treat over 600 patients, forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation CAR-Ts designed for best-in-class opportunities in hematological malignancies and B-cell driven autoimmune diseases like lupus. Our allogeneic T cells are manufactured from healthy donors without T-cell receptor (TCR) or major histocompatibility complex (MHC) gene editing so T cells can retain their natural attributes and cell fitness. By preferentially manufacturing T cells that only recognize EBV, together with partial MHC matching, graft-versus-host disease and host rejection are mitigated while retaining effector function through CAR and antigen binding. A molecular toolkit of clinically-validated technologies—including the 1XX costimulatory domain designed for better cell fitness, potency, and less exhaustion while maintaining stemness—offers a differentiated approach to addressing significant unmet needs with the next generation CAR T. Atara is headquartered in Southern California.